home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9409d.zip
/
M9490760.TXT
< prev
next >
Wrap
Text File
|
1994-09-24
|
4KB
|
57 lines
Document 0760
DOCN M9490760
TI Epstein-Barr virus (EBV) replicative gene expression in tumour cells of
AIDS-related non-Hodgkin's lymphoma in relation to CD4 cell number and
antibody titres to EBV.
DT 9411
AU Brousset P; Drouet E; Schlaifer D; Icart J; Payen C; Meggetto F; Marchou
B; Massip P; Delsol G; Department of Pathology, Centre Hospitalier
Universitaire de; Purpan, Toulouse, France.
SO AIDS. 1994 May;8(5):583-90. Unique Identifier : AIDSLINE MED/94338593
AB OBJECTIVE: To determine whether activation of Epstein-Barr virus (EBV)
replication in tumour cells of AIDS-related non-Hodgkin's lymphoma
(ARNHL) is correlated with CD4+ cell counts and influences antibody
response to EBV [anti-Z Epstein-Barr replicative activator (ZEBRA),
anti-early antigen (EA), anti-viral capsid antigen (VCA)]. DESIGN:
Retrospective study based on immunohistochemistry and in situ
hybridization to detect EBV replicative gene products in tissue samples
from patients affected by ARNHL and correlation with CD4+ cell counts
and results of EBV serology (including anti-ZEBRA activity) in sera from
the same patients. METHODS: Seventeen out of 22 cases of ARNHL were
selected for the presence of EBV [Epstein-Barr early region (EBER)
RNA-positive]. Immunohistochemistry was performed with anti-ZEBRA,
anti-EA-restricted, anti-VCA antibodies and in situ hybridization with
BHLF1/NotI oligoprobes on tumour samples. Results were statistically
correlated with those of CD4+ cell counts (17 out of 17) and with
anti-EBV antibody titres (13 out of 17) assessed using standard
immunofluorescence method and enzyme-linked immunosorbent assay
procedure using recombinant ZEBRA protein and synthetic peptides as
antigens. RESULTS: BZLF1 (ZEBRA) or early gene products (EA-R and
EA-D/BHLF1/NotI) were detected in a small proportion (< 0.01-5%) of
tumour cells in eight of these 17 cases by immunohistochemistry and in
situ hybridization. Demonstration of replicative gene expression did not
correlate with either low CD4+ cell counts (P > 0.05) or anti-EBV
antibody titres (P > 0.05). Anti-ZEBRA activity was not significantly
increased in patients affected with ARNHL, the cells of which expressed
replicative gene products (P > 0.05). CONCLUSION: The degree of
immunodeficiency does not clearly enhance replicative gene expression in
tumour cells of ARNHL. EBV serology, including anti-ZEBRA activity, is
not a reliable tool for predicting the occurrence of such
proliferations.
DE Acquired Immunodeficiency Syndrome/COMPLICATIONS Adult Antibodies,
Viral/BIOSYNTHESIS/*BLOOD Antibody Specificity Antigens,
Viral/BIOSYNTHESIS/GENETICS/IMMUNOLOGY DNA-Binding
Proteins/BIOSYNTHESIS/GENETICS/IMMUNOLOGY Enzyme-Linked Immunosorbent
Assay Female *Gene Expression Regulation, Neoplastic *Gene Expression
Regulation, Viral Herpesviridae Infections/COMPLICATIONS Herpesvirus
4, Human/*GENETICS/IMMUNOLOGY/PHYSIOLOGY Human Leukocyte Count
Lymphoma, AIDS-Related/*MICROBIOLOGY Male Middle Age Retrospective
Studies Support, Non-U.S. Gov't
Trans-Activators/BIOSYNTHESIS/GENETICS/IMMUNOLOGY Tumor Virus
Infections/COMPLICATIONS *T4 Lymphocytes *Virus Activation Virus
Replication JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).